抗整合素抗体αvβ6在溃疡性结肠炎诊断中的应用

doi:10.3969/j.issn.1004-583X.2026.06.015

摘要/Abstract

摘要：

溃疡性结肠炎(ulcerative colitis,UC)是一种慢性炎症性肠病,其早期诊断及疾病评估仍存在一定挑战。近年来,抗整合素抗体αvβ6作为新型免疫学标志物,在UC诊断中的价值逐渐受到关注。αvβ6在UC肠黏膜中异常表达,与上皮屏障损伤及免疫炎症反应相关。文章对该抗体诊断UC的特异度与敏感度、联合粪钙素/粪钙卫蛋白等标志物的临床应用价值及其在疾病预后评估中的作用进行综述,并探讨其在特殊UC群体中的潜在应用前景。

关键词: 结肠炎, 溃疡性, 抗整合素αvβ6抗体, 诊断, 治疗

中图分类号:

R574.62

张艳丽, 赵朕华, 张敬知, 孟庆顺. 抗整合素抗体αvβ6在溃疡性结肠炎诊断中的应用[J]. 临床荟萃, 2026, 41(6): 568-571.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.06.015

https://www.lchc.cn/CN/Y2026/V41/I6/568

参考文献 33

[1]	Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778.doi: 10.1016/S0140-6736(17)32448-0.
[2]	杨红, 钱家鸣. 《中国溃疡性结肠炎诊治指南(2023年·西安)》解读[J]. Beijing Med, 2024, 46(11): 999-1002. doi:10.15932/j.0253-9713.2024.11.017.
[3]	Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: Ulcerative colitis in adults[J]. Am J Gastroenterol, 2025, 120(6): 1187-1224.doi: 10.14309/ajg.0000000000003463. pmid: 40701556
[4]	Acevedo D, Salvador MP, Girbes J, et al. Fecal calprotectin: A comparison of two commercial enzymoimmunoassays and study of fecal extract stability at room temperature[J]. J Clin Med Res, 2018, 10(5): 396.doi: 10.14740/jocmr3275e. pmid: 29581802
[5]	Li T, Jing H, Gao X, et al. Identification of key genes as diagnostic biomarkers for IBD using bioinformatics and machine learning[J]. J Transl Med, 2025, 23(1): 738. doi:10.1186/s12967-025-06531-1. pmid: 40611294
[6]	Barczyk M, Carracedo S, Gullberg D. Integrins[J]. Cell and Tissue Research, 2009, 339(1): 269-280. doi:10.1007/s00441-009-0834-6.
[7]	Yu Y, Chen S, Lu GF, et al. Alphavbeta6 is required in maintaining the intestinal epithelial barrier function[J]. Cell Biol Int, 2014, 38(6): 777-781. doi:10.1002/cbin.10258. pmid: 24677750
[8]	Koivisto L, Bi J, Häkkinen L, et al. Integrin αvβ6: Structure, function and role in health and disease[J]. Int J Biochem Cell Biol, 2018, 99: 186-196.doi: 10.1016/j.biocel.2018.04.013. pmid: 29678785
[9]	Roth D, Düll MM, Horst LJ, et al. Integrin αVβ6 as autoantigen and driver of epithelial remodeling in IBD[J]. J Crohns Colitis, 2025, 19(2): jjae131. doi:10.1093/ecco-jcc/jjae131.
[10]	Pertsinidou E, Salomon B, Bergemalm D, et al. Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype[J]. Crohns Colitis, 2025, 19(5):jjaf062. doi:10.1093/ecco-jcc/jjaf062.
[11]	Nihira H, Shiokawa M, Izawa K, et al. Anti-integrin αvβ6 antibody as a diagnostic marker for pediatric patients with ulcerative colitis[J]. Gastroenterology, 2022, 163(4): 1094-1097.e14. doi:10.1053/j.gastro.2022.06.026. pmid: 35709831
[12]	Nakanishi R, Kuwada T, Shiokawa M, et al. Anti-integrin αvβ6 antibodies predict pouchitis after IPAA[J]. Inflamm Bowel Dis, 2025, 31(3): 777-785. doi:10.1093/ibd/izae263. pmid: 39657162
[13]	Ishikawa Y, Yoshida H, Yoshifuji H, et al. Anti-integrin αvβ6 antibody in Takayasu arteritis patients[J]. Front Immunol, 2024, 15: 1387516. doi:10.3389/fimmu.2024.1387516.
[14]	Livanos AE, Dunn A, Fischer J, et al. Autoantibodies against endothelial protein C receptor and integrin αvβ6 predict the development of ulcerative colitis[J]. Gastroenterology, 2024, 167(1): 238-250.e8. doi:10.1053/j.gastro.2024.04.023.
[15]	Yamamoto S, Kuwada T, Shiokawa M, et al. Anti-integrin αvβ6 antibody titer as a predictive biomarker of future treatment escalation[J]. Gastro Hep Adv, 2025, 4(3): 100582. doi:10.1016/j.gastha.2024.10.022.
[16]	Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis[J]. Gastroenterology, 2021, 160(7): 2383-2394.e21. doi:10.1053/j.gastro.2021.02.019. pmid: 33582126
[17]	Chen H, Chen L, Wang X, et al. Transgenic overexpression of ITGB6 exacerbates DSS-induced colitis in mice[J]. J Cell Mol Med, 2021, 25(5): 2679-2690. doi: 10.1111/jcmm.v25.5 URL
[18]	Sun Q, Lu Z, Ma L, et al. Integrin β6 deficiency protects mice from experimental colitis and colitis-associated carcinoma[J]. Front Oncol, 2023, 13: 1190229. doi:10.3389/fonc.2023.1190229.
[19]	Marafini I, Laudisi F, Salvatori S, et al. Diagnostic value of anti-integrin αvβ6 antibodies in ulcerative colitis[J]. Dig Liver Dis, 2024, 56(1): 55-60. doi:10.1016/j.dld.2023.06.024.
[20]	Livanos AE, Dunn A, Fischer J, et al. Anti-integrin αvβ6 autoantibodies antedate ulcerative colitis[J]. Gastroenterology, 2023, 164(4): 619-629. doi:10.1053/j.gastro.2022.12.042.
[21]	Okabe M, Yamamoto S, Shiokawa M, et al. Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis[J]. J Gastroenterol, 2025, 60(1): 86-95. doi:10.1007/s00535-024-02176-x.
[22]	Bez P, Scapolan M, Ribaldone DG, et al. Antibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis[J]. Front Immunol, 2025, 16: 1641329. doi: 10.3389/fimmu.2025.1641329 URL
[23]	Nisar M, Awan AR, Ahmad A, et al. Diagnostic accuracy of anti-integrin αvβ6 in ulcerative colitis: A meta-analysis[J]. J Gastroenterol, 2025: 1-15.
[24]	Pertsinidou E, Salomon B, Bergemalm D, et al. Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype[J]. J Crohns Colitis, 2025, 19(5): jjaf062. doi:10.1093/ecco-jcc/jjaf062.
[25]	Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for IBD[J]. Am J Gastroenterol, 2007, 102(4): 803-813. doi: 10.1111/ajg.2007.102.issue-4 URL
[26]	Kapel N, Ouni H, Benahmed NA, et al. Fecal calprotectin for diagnosis and management of inflammatory bowel diseases[J]. Clin Transl Gastroenterol, 2023, 14(9): e00617. doi: 10.14309/ctg.0000000000000617 URL
[27]	Stevens TW, Gecse K, Turner JR, et al. Diagnostic accuracy of fecal calprotectin concentration in ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2021, 19(11): 2333-2342. doi: 10.1016/j.cgh.2020.08.019 URL
[28]	Sasidharan S, Sasson AN, Shannon KM, et al. Fecal calprotectin predicts need for rescue therapy in severe colitis[J]. Inflamm Bowel Dis, 2022, 28(12): 1833-1837. doi: 10.1093/ibd/izac011 pmid: 35134899
[29]	Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS using fecal and blood markers[J]. Inflamm Bowel Dis, 2008, 14(1): 32-39. doi:10.1002/ibd.20275. pmid: 17924558
[30]	Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease[J]. Digestion, 2023, 104(1): 30-41. doi: 10.1159/000527846 URL
[31]	Smith J, Doe A, Chen L, et al. Inflammatory bowel disease and pANCA: A systematic review[J]. J Gastroenterol Hepatol, 2023, 15(4): 123-135. doi:10.1002/jgh.12345.
[32]	Mendieta-Escalante EA, Faber KN, Dijkstra G. Current and emerging autoantibodies in ulcerative colitis[J]. Eur J Immunol, 2025, 55(8): e51721. doi: 10.1002/eji.v55.8 URL
[33]	Yokode M, Shiokawa M, Kawakami H, et al. Anti-integrin αvβ6 autoantibodies in immune checkpoint inhibitor-induced colitis[J]. Br J Cancer, 2024, 130(9): 1552-1560. doi:10.1038/s41416-024-02647-1.

抗整合素抗体αvβ6在溃疡性结肠炎诊断中的应用

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	欧阳芊, 赵颖, 孟珩, 徐安定. 缺血性卒中急性期的抗血小板治疗[J]. 临床荟萃, 2026, 41(6): 485-492.
[2]	周颖, 周芳芳. 急性肾损伤新型生物标志物的研究进展[J]. 临床荟萃, 2026, 41(5): 475-480.
[3]	李鑫月, 李世豪, 刘娜, 吴婧, 李美玲, 刘改芳. CC趋化因子配体调控胃癌的研究现状及进展[J]. 临床荟萃, 2026, 41(4): 363-368.
[4]	刘一坤, 张明, 刘倩, 孙绍婷, 李媛媛, 杜书同. 连续性肾脏替代治疗在脓毒症合并急性肾损伤中的研究进展[J]. 临床荟萃, 2026, 41(4): 374-379.
[5]	姜俊辰, 郭蓉娟, 张帆, 刘佳霖. MAPK信号通路在脑出血中的研究进展[J]. 临床荟萃, 2026, 41(3): 269-273.
[6]	刘栋, 杨启昌, 李欣然. 抑郁症与肠道菌群关联性的研究进展及趋势分析[J]. 临床荟萃, 2026, 41(3): 285-288.
[7]	张艳萍, 李坷, 张壮. 心房颤动相关急性脑梗死早期启动抗凝治疗的安全性[J]. 临床荟萃, 2026, 41(2): 116-121.
[8]	河北医科大学第二医院神经外科癫痫亚专业组人工智能诊断模型辅助癫痫脑电图诊断专家共识工作组. 人工智能诊断模型辅助癫痫脑电图诊断专家共识[J]. 临床荟萃, 2026, 41(2): 164-168.
[9]	郝清卿, 张飞飞, 吕仕林. 单纯药物涂层球囊在冠状动脉介入治疗中的研究进展[J]. 临床荟萃, 2026, 41(2): 188-192.
[10]	孙振晓, 张继香. 音乐强迫性障碍1例并文献复习[J]. 临床荟萃, 2026, 41(1): 64-67.
[11]	潘炎, 严晓华, 焦富勇. 川崎病流行病学现状、争议及展望[J]. 临床荟萃, 2025, 40(9): 861-864.
[12]	赵伟, 徐慧娟, 赵艳霞, 王玲珍, 卢愿, 杨静. 婴儿恶性石骨症1例并文献复习[J]. 临床荟萃, 2025, 40(8): 726-730.
[13]	陈文江, 舒展, 周来显. 基于核酸适配体的肺癌诊断和治疗研究进展[J]. 临床荟萃, 2025, 40(8): 742-747.
[14]	孙楠, 杨凯琦, 唐亚赛, 谢小华, 吕佩源, 董艳红. 帕金森病认知障碍的治疗新进展[J]. 临床荟萃, 2025, 40(8): 748-752.
[15]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.